Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ANB101
- Development stage
- Unknown
- Lead developer
- AnaptysBio
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous (based On Typical Administration Route For Monoclonal Antibodies In Early Phase Trials; Subcutaneous May Also Be Possible But Not Explicitly Confirmed)
01
Overview
ANB101 is a monoclonal antibody that acts as a modulator of BDCA2, a molecule specifically expressed on plasmacytoid dendritic cells (pDCs). By binding to BDCA2, ANB101 potently inhibits interferon secretion and immune activation by pDCs. This mechanism is designed to reduce inflammation while preserving the tolerogenic potential of pDCs. The drug is being developed for the treatment of autoimmune and inflammatory diseases where pDC-driven interferon production plays a pathogenic role. ANB101 is currently in Phase 1 clinical trials in healthy volunteers. The program was originally licensed from Centessa Pharmaceuticals and is now being developed by AnaptysBio[1][2][3][5].
- Other names
- CBS004CBS-004CBS 004ANB-101ANB101ANB 101
02
Targets
CLEC4C (C-type lectin domain family 4 member C)
Beyond the preview
Go deeper on ANB101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ANB101.